It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
We studied which retinal area controls short-term axial eye shortening when human subjects were exposed to + 3.0D monocular defocus. A custom-built infrared eye tracker recorded the point of fixation while subjects watched a movie at a 2 m distance. The eye tracker software accessed each individual movie frame in real-time and covered the points of fixation in the movie with a uniform grey patch. Four patches were programmed: (1) foveal patch (0–3 degrees), (2) annular patch (3–9 deg), (3) foveal patch (0–3 deg) combined with an annular patch (6–9 deg), and (4) full-field patch where only 6–10 deg were exposed to the defocus. Axial eye shortening was elicited similarly with full-field positive defocus and with the foveal patch, indicating that the fovea made only a minor contribution (-11 ± 12 μm vs. -14 ± 17 μm, respectively, n.s.). In contrast, patching a 3–9 degrees annular area or fovea together with an annular area of 6–9 degrees, completely suppressed the effect when compared with full-field defocus (+ 3 ± 1 μm or -2 ± 13 μm vs. -11 ± 12 μm, respectively, p < 0.001). Finally, we found that the near-peripheral retina (6–10 degrees) is a “sweet spot” for positive defocus detection and alone can regulate eye growth control mechanism, and perhaps long-term refractive development (-9 ± 8 μm vs. full-field: -11 ± 12 μm, n.s.).
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Institute of Molecular and Clinical Ophthalmology Basel (IOB), Basel, Switzerland (GRID:grid.508836.0) (ISNI:0000 0005 0369 7509)
2 University of Basel, Basel, Switzerland (GRID:grid.6612.3) (ISNI:0000 0004 1937 0642); Medical University of Vienna, Department of Clinical Pharmacology, Vienna, Austria (GRID:grid.22937.3d) (ISNI:0000 0000 9259 8492)
3 Institute of Molecular and Clinical Ophthalmology Basel (IOB), Basel, Switzerland (GRID:grid.508836.0) (ISNI:0000 0005 0369 7509); University of Tuebingen, Section of Neurobiology of the Eye, Ophthalmic Research Institute, Tuebingen, Germany (GRID:grid.10392.39) (ISNI:0000 0001 2190 1447); University of Tuebingen, Zeiss Vision Lab, Institute of Ophthalmic Research, Tuebingen, Germany (GRID:grid.10392.39) (ISNI:0000 0001 2190 1447)